StonvexLoading…
StonvexStonvexStonvexReal-time TradingView chart with full indicator set.
Last 7 days, powered by Finnhub. Tap Analyze to classify direction.
Loading latest news…
Factor grades, AI Copilot, personalized ranking, and deeper event analysis.
Upgrade to Pro →Share this analysis with other traders
Disclaimer: The content on this page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making any investment decisions.
Sign in to jot down a private note about ICCC. Only you ever see it.
Pick the depth your tier unlocks. Logged-in Pro/Premium users automatically get the deeper report.
Free preview · 3 reports / hour · No sign-up required
External sites have their own terms, paywalls, and accuracy standards. Stonvex doesn't endorse the content there.
Three bull points, three bear points, and one “what would change my mind” line — both sides forced onto one screen as a research note rather than a tip sheet.
Next report date, year-over-year trend, and recent quarter history.
ImmuCell Corp is an animal health biologics company focused on the development, manufacture, and commercialization of products intended to improve the survivability, health, and long-term performance of neonatal dairy and beef calves. Its product, First Defense, utilizes hyperimmunized bovine colostrum to provide pathogen-specific antibodies and other bioactive components. First Defense is designed to provide Immediate Immunity through orally delivered antibodies against the principal viral and bacterial causes of neonatal calf diarrhea (scours), including Escherichia coli (E.coli), bovine coronavirus, and bovine rotavirus. It has two operating segments: Scours and Mastitis. It derives the majority of the revenue from the Scours segment that consists of the First Defense product line.
Earnings (▲ beat / ▼ miss) and ex-dividend dates plotted on the price line. Educational — proximity does not establish causation.
Past 1 reported quarters: EPS surprise vs estimate and the day-after-release stock reaction. Past performance does not predict future moves.
Sources: Finnhub earnings calendar + Polygon daily aggregates. Reaction direction can diverge from EPS surprise (guidance, macro, or sector flow can dominate the next-day print).
Indicator values from Polygon. Educational only — single- indicator triggers in isolation are not a complete trading signal.
Documents are served directly from sec.gov / the issuer's website — Stonvex does not proxy or store filings.
5-factor analysis: Valuation, Growth, Profitability, Momentum, Financial Health.
Each factor shows ICCC's percentile within the scored universe — observational ranking, not a recommendation.
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
| Metric | Q1 2026 2026-03-31 | Annual 2025 2025-12-31 | Q3 2025 2025-09-30 | Q1 2025 2025-03-31 |
|---|---|---|---|---|
Revenue | $10.36M | $27.64M | $20.02M | $8.07M |
Operating Income | $1.97M | $1.65M | $1.71M | $1.12M |
Net Income | $1.94M | $-1.04M | $1.81M | $1.45M |
EPS (Diluted) | $0.21 | $-0.12 | $0.20 | $0.16 |
Total Assets | $44.11M | $42.53M | $45.73M | $45.62M |
Total Liabilities | $14.97M | $15.48M | $15.93M | $16.63M |
Cash & Equivalents | $6.81M | $3.81M | $3.89M | $4.60M |
Free Cash Flow OCF − CapEx | $3.40M | $1.22M | $914.62K | $1.24M |
Shares Outstanding | 9.05M | 9.05M | 9.05M | 8.98M |